Press Release // January 20, 2025 Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® FYB203 (aflibercept) approved for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases AHZANTIVE® and Baiama® offer patients treat [ … ]

Press Release // January 15, 2025 Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi®received MHRA approval for both subcutaneous and intravenous formulations, to treat serious inflammatory diseases UK approval follows the series of successful approvals by the FDA, the European Co [ … ]

Presse Release // January 13, 2025   Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel Planegg-Martinsried, Germany – Klinge Biopharma GmbH (Klinge), the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimila [ … ]

Press Release // January 9, 2025   Formycon included in TecDAX Index of Deutsche Börse Formycon to join the ranks of the 30 leading listed technology companies Uplisting to the Prime Standard, inclusion in the SDAX, and robust business development further enhance the stock’s appeal Entry into the TecDAX becomes effective as of January 13, 2025  [ … ]

Press Release // January 8, 2025 Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi® approved by Health Canada for both subcutaneous and intravenous formulations to treat serious inflammatory diseases Health Canada joins the FDA and the European Commission in gra [ … ]